Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Piperacillin Sodium

FDA-approved product (injectable, injection), marketed as Piperacillin, Pipracil.

Registered studies
50+
Lab records
245
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Piperacillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Appendicitis
  • Bacterial disease
  • Cellulitis
  • Diabetic foot
  • Endometritis
  • Pelvic Inflammatory Disease
  • Peritonitis
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Penicillins with extended spectrum
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CA12

Repurposing investigation

Piperacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA92.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli16.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 12 lab records
  • E. coli: measured active in 10 of 42 lab records
  • K. pneumoniae: measured active in 30 of 191 lab records
Open Piperacillin Sodium in ChEMBL Registered studies below
Show the latest 150 of 245 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Piperacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS

    NCT07675018 · start 2026-09-15

    Registered record
    Registry ID
    NCT07675018
    Conditions
    Drug Resistance, Microbial; Biomarkers; Urinary Tract Infections (UTI's); Antibacterial Agents
    Interventions
    Detection of integrons; Gold standard
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-09-15
    Completion
    2028-09-21
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Resistance, Microbial; Biomarkers; Urinary Tract Infections (UTI's); Antibacterial Agents
    InterventionDetection of integrons; Gold standard
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Aminoglycosides in Early Sepsis

    NCT06712641 · start 2026-04-23

    Registered record
    Registry ID
    NCT06712641
    Conditions
    Sepsis
    Interventions
    Gentamicin + narrow spectrum betalactam; Cefotaxime; Piperacillin-tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04-23
    Completion
    2033-05
    Enrolment
    1,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionGentamicin + narrow spectrum betalactam; Cefotaxime; Piperacillin-tazobactam
    PhasePhase 4
    Registry statusRecruiting

  • Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis

    NCT06977165 · start 2025-09-01

    Registered record
    Registry ID
    NCT06977165
    Conditions
    Respiration Disorders; Respiratory Failure; Sepsis; Infection in ICU; Pneumonia
    Interventions
    Antibiotic quantification
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2027-09-30
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiration Disorders; Respiratory Failure; Sepsis; Infection in ICU +1 more
    InterventionAntibiotic quantification
    PhaseNot recorded
    Registry statusNot yet recruiting

  • eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

    NCT05753735 · start 2024-01-18

    Registered record
    Registry ID
    NCT05753735
    Conditions
    Pancreatic Fistula
    Interventions
    Piperacillin/Tazobactam; Amoxicillin/ Clavulanic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2024-01-18
    Completion
    2024-06-02
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Fistula
    InterventionPiperacillin/Tazobactam; Amoxicillin/ Clavulanic acid
    PhasePhase 2
    Registry statusTerminated

  • Therapeutic Drug Monitoring - Targeting IMproved Effectiveness

    NCT05971979 · start 2023-12-12

    Registered record
    Registry ID
    NCT05971979
    Conditions
    Pneumonia; Sepsis; Infection, Bacterial
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-12-12
    Completion
    2024-06-21
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Sepsis; Infection, Bacterial
    InterventionNo intervention
    PhaseNot recorded
    Registry statusCompleted

  • Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations

    NCT06076200 · start 2023-09-30

    Registered record
    Registry ID
    NCT06076200
    Conditions
    Early-Onset Neonatal Sepsis
    Interventions
    Piperacillin Sodium and Tazobactam Sodium for Injection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-09-30
    Completion
    2026-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly-Onset Neonatal Sepsis
    InterventionPiperacillin Sodium and Tazobactam Sodium for Injection
    PhaseNot recorded
    Registry statusRecruiting

  • Comparing Oral Versus Parenteral Antimicrobial Therapy

    NCT05977868 · start 2023-08-04

    Registered record
    Registry ID
    NCT05977868
    Conditions
    Endovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection; Gastrointestinal Infection; Genitourinary Infection
    Interventions
    Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-08-04
    Completion
    2025-02-14
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection +2 more
    InterventionAmoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    PhasePhase 4
    Registry statusTerminated

  • Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit

    NCT05565222 · start 2023-03-11

    Registered record
    Registry ID
    NCT05565222
    Conditions
    Sepsis; Septic Shock
    Interventions
    Piperacillin/tazobactam or temocillin; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-03-11
    Completion
    2026-06
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Septic Shock
    InterventionPiperacillin/tazobactam or temocillin; Meropenem
    PhasePhase 3
    Registry statusUnknown

  • Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.

    NCT04276480 · start 2022-02-16

    Registered record
    Registry ID
    NCT04276480
    Conditions
    Enterobacteriaceae Infections
    Interventions
    Piperacillin-tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-02-16
    Completion
    2024-04-22
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnterobacteriaceae Infections
    InterventionPiperacillin-tazobactam
    PhaseNot applicable
    Registry statusCompleted

  • Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections

    NCT05060419 · start 2021-10-08

    Registered record
    Registry ID
    NCT05060419
    Conditions
    Complicated Urinary Tract Infection; Acute Pyelonephritis
    Interventions
    Meropenem- FL058; Piperacillin -tazobactam; Saline; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-10-08
    Completion
    2022-08-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection; Acute Pyelonephritis
    InterventionMeropenem- FL058; Piperacillin -tazobactam; Saline; Saline
    PhasePhase 2
    Registry statusUnknown

  • PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

    NCT04983901 · start 2021-09-14

    Registered record
    Registry ID
    NCT04983901
    Conditions
    Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    Interventions
    Imipenem/Cilastatin/Relebactam; Cefepime; Meropenem; Piperacillin-Tazobactam; Vancomycin; Daptomycin; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-14
    Completion
    2023-10-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    InterventionImipenem/Cilastatin/Relebactam; Cefepime; Meropenem; Piperacillin-Tazobactam +3 more
    PhasePhase 2
    Registry statusCompleted

  • Are Standard Dosing Regimens of Piperacillin-Tazobactam Suitable in Critically Ill Patients With Open Abdomen and Negative Pressure Wound Therapy? A Population Pharmacokinetic Study.

    NCT04915872 · start 2021-07-01

    Registered record
    Registry ID
    NCT04915872
    Conditions
    Laparotomy; Critical Illness; Piperacillin, Tazobactam Drug Combination
    Interventions
    Blood sampling (T0, inclusion); other samplings (T1)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-07-01
    Completion
    2023-01-27
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLaparotomy; Critical Illness; Piperacillin, Tazobactam Drug Combination
    InterventionBlood sampling (T0, inclusion); other samplings (T1)
    PhaseNot recorded
    Registry statusCompleted

  • RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

    NCT04514653 · start 2020-08-25

    Registered record
    Registry ID
    NCT04514653
    Conditions
    Neovascular Age-Related Macular Degeneration (nAMD)
    Interventions
    Ranibizumab; ABBV-RGX-314 Dose 1; ABBV-RGX-314 Dose 2; ABBV-RGX-314 Dose 3; Local Steroid; Topical Steroid; ABBV-RGX-314 Dose 4
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-08-25
    Completion
    2027-02
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeovascular Age-Related Macular Degeneration (nAMD)
    InterventionRanibizumab; ABBV-RGX-314 Dose 1; ABBV-RGX-314 Dose 2; ABBV-RGX-314 Dose 3 +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

    NCT03862079 · start 2020-06-01

    Registered record
    Registry ID
    NCT03862079
    Conditions
    Graft-versus-host Disease Prevention
    Interventions
    Best Practice; Fecal Microbiota Transplantation; Nystatin; Piperacillin-Tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-06-01
    Completion
    2021-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft-versus-host Disease Prevention
    InterventionBest Practice; Fecal Microbiota Transplantation; Nystatin; Piperacillin-Tazobactam
    PhasePhase 2
    Registry statusWithdrawn

  • Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD

    NCT04879030 · start 2020-01-01

    Registered record
    Registry ID
    NCT04879030
    Conditions
    COPD Exacerbation Acute
    Interventions
    Beta-Lactams; Fluoroquinolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2020-12-30
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD Exacerbation Acute
    InterventionBeta-Lactams; Fluoroquinolone
    PhasePhase 2 / Phase 3
    Registry statusCompleted